A randomised active controlled study of AMG 162 in breast cancer subjects with bone metastases who have not previously been treated with bisphosphonate therapy

To evaluate the effect of different doses and schedules of AMG 162 on the percent change from baseline in urinary N-telopeptide (uNTx) at week 13